Artificial intelligence in precision medicine:
Development of predictive platforms
for cancer
Advancement of Research, Development, Innovation projects (R+D+I)
Through our Research, Development and Innovation Department, comprised by prestigious professionals from different scientific areas, we actively developed numerous innovation projects in precision medicine, in genetic and molecular areas, in which we studied the presence of mutations in different genes for different types of tumors and incorporated new technologies with new genomic alteration detection methods.
Are you a professional? Suggest a project Are you a professional?Suggest a project
Some of the active projects and in advanced stages of development
Bioinformatics & Tumor BioBank
- A Biobank of tumors in advanced stages, in compliance with the highest international quality standards, for the purpose of advancing research and development strategies in collaboration with drug development, and drug and biomarker discovery processes.
- Patients who have given their consent to anonymize, encrypt, and donate their information for research purposes, to promote the development of new, more effective, and personalized therapies, with the aim of helping millions of patients around the world live a longer and better life.
- For clinical and genomic data collection, together with documentation, analysis, and assessment of the information developed by a team of scientific and bioinformatics specialists.
- BIOMAKERS can develop and provide clinical program services based on a retrospective analysis of samples, and genomic and molecular support to accompany the launch of new molecules to the market.
Tumor BioBank Department
Unique Cancer Testing Platform
PLUTÓN is the Unique Oncology Testing Platform, which allows each professional to digitally, quickly and easily solve the molecular testing for all of their patients.
Therefore, in addition to concentrating all the tested cases with their results in a single scientific, interactive and intuitive platform, and in addition to requesting additional genomic tests, health professionals will also be able to generate their own statistics and compare them with the scientific literature, check therapeutic recommendations based on analyses developed by experts and bioinformaticians, and interrelate clinical and genomic variables from each of their patients.
Enter Pluton*The name and information do not correspond to a real patient.
